DAO

MONTRÉAL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the fiscal year ended July 31, 2023. According to Paul Baehr, IBEX President and CEO, “We were pleased by the overall F2023 performance when compared to an exceptional F2022, and in particular, with the Company’s performance as compared to F2021 and F2020.” Highlights: Revenues for the year were only 5% lower than F2022, well above expectations, and were 41% higher than the benchmark F2021. Earnings before tax were down 15% as compared to F2022, but up over 200% when compared to F2021 & F2020. Year-ending cash and cash equivalents were $8,547,043, up 12% vs F2022 and up 193% vs F2021. Mr. Baehr further stated, “Looking forward we expect F2024 results to be in line with F2023.” Revenues are expected to be in the F2023 range, with continued strong growth in the hemostasis business. Offsetting the strong growth in hemostasis is the negative impact of the Company’s exit from the marginally-profitable Arthritis ELIZA kit business and some softness in other reagent customers. Earnings before tax for F2024 are expected to be in line with F2023. Year-ending cash is expected to reach $10M, an increase of 17%. Note: All figures are in Canadian dollars unless otherwise stated. The Company’s audited consolidated financial statements for the year ended July 31, 2023 and the accompanying notes and the related management’s discussion and analysis is found on the Company’s website at or under the Company’s pro SEDAR at FINANCIAL RESULTS FOR THE FOURTH QUARTER OF FISCAL 2023 Revenues for the quarter ended July 31, 2023 totaled $1,753,902, decreasing by $316,112 (15%) from $2,070,014 in the same period last year. Expenses before tax totaling $1,397,079 were up by $74,257 vs same quarter a year ago, relating to many offsetting factors: a negative foreign exchange impact of $64,935 and an increase in salaries & benefits of $63,459 mainly due to a higher Profit-Sharing Plan accrual in the quarter; offset by a decrease in finance expenses of $69,446 driven by interest on the cash balances. The company recorded earnings before tax for the quarter of $356,623 down $390,369 versus earnings before tax of $746,992 on a comparable basis in Fiscal 2022. The increase in net earnings to $2,223,643 from $34,764 in the same period last year is mainly due to a tax reorganization resulting in the recording of previously unrecorded tax assets on the balance sheet. This led to an income tax recovery of $1,867,020 for the quarter versus an income tax expense of $712,228 in the same quarter last year. The decrease in earnings before tax for the quarter, led the Company to record an EBITDA of $383,570 versus $815,219 in the same period year ago. EBITDA for the three months ended July 31, 2023 July 31, 2022 Net earnings $2,223,643 $34,764 Depreciation of property, plant, equipment and intangible assets $53,555 $34,370 Depreciation of right-of-use assets $68,341 $57,627 Interest – Net ($94,949 ) ($23,770 ) Income tax expense (recovery) ($1,867,020 ) $712,228 Earnings before interest, tax, depreciation and amortization $383,570 $815,219 It should be noted that “EBITDA” (Earnings Before Interest, Tax, Depreciation & Amortization) is not a performance measure defined by IFRS, but we, as well as investors and analysts, consider that this performance measure facilitates the evaluation of our ongoing operations and our ability to generate cash flows to fund our cash requirements, including our capital expenditures program. Note that our definition of this measure may differ from the ones used by other public corporations. FINANCIAL RESULTS FOR THE YEAR Revenues for the year ended July 31, 2023 totaled $7,491,739 compared to $7,892,487 in the prior year, a decrease of 5%. Expenses before taxes totaled $5,473,925, a decrease of $31,939. This small variance is due to many offsetting factors, mainly: an increase in R&D costs of $323,210 offset by an increase in SR&ED tax credits of $277,401 for the year. Lower finance expenses of $292,137 driven by interest income on the cash balances offsets the negative foreign exchange impact of $151,356. As mentioned above, the company recognized previously unrecognized tax assets resulting in an income tax recovery for the year ended July 31, 2023. Due to this tax recovery, net earnings totaled $3,893,614 compared to net earnings in FY2022 of $1,674,395. The company recorded EBITDA of $2,161,702 versus $2,760,885 in the same period last year, a decrease of $599,183, due mainly to the decrease in revenues. Financial Summary for the year ended July 31, 2023 July 31, 2022 Revenues $7,491,739 $7,892,487 Earnings before interest, tax, depreciation & amortization (EBITDA) $2,161,702 $2,760,885 Depreciation of property, plant, equipment and intangible assets $171,444 $149,214 Depreciation of right-of-use assets $265,611 $220,719 Net earnings $3,983,614 $1,674,395 Earnings per share $0.16 $0.07 EBITDA for the year ended July 31, 2023 July 31, 2022 Net earnings $3,893,614 $1,674,395 Depreciation of property, plant, equipment and intangible assets $171,444 $149,214 Depreciation of right-of-use assets $265,611 $220,719 Interest - Net ($293.167 ) $4,329 Income tax expense (recovery) ($1,875,800 ) $712,228 Earnings before interest, taxes, depreciation and amortization $2,161,702 $2,760,885 Cash and cash equivalents increased by $905,991 to $8,547,043 during the year ended July 31, 2023 as compared to the year ended July 31, 2022. Net working capital reached $8,429,764, an increase of $1,155,431 from FY2022. Balance Sheet Summary as at July 31, 2023 July 31, 2022 Cash and cash equivalents $8,547,043 $7,641,052 Net working capital $8,429,764 $7,274,333 Outstanding shares at report date (common shares) 24,644,244 24,784,244 NCIB On July 17, 2023, the Company announced that the Toronto Stock Venture Exchange approved the renewal of the Normal Course Issuer Bid (“2024 NCIB”) that was originally launched on July 29, 2022. Under the terms of the 2024 NCIB, the Company may purchase for cancellation up to 1,500,000 common shares of the Company, which represented 10% of its public float as at July 14, 2023. The new 2024 NCIB commenced on August 5, 2023 and will end on the earlier of August 4, 2024 or when the Company completes its maximum purchases under the NCIB. Furthermore, IBEX entered into an agreement with a broker to facilitate purchases of its common shares under the NCIB. Under IBEX’s automatic share purchase plan, the broker may purchase common shares, which would ordinarily not be permitted due to regulatory restrictions or self-imposed blackout periods. After year-end and as of the date of the financial statements, 64,600 shares were repurchased and cancelled for a total of $42,584 for the original 2023 NCIB and 114,400 shares have been repurchased for the 2024 NCIB for a total of $111,820. LOOKING FORWARD As always, the future financial results of the Company are difficult to predict as the Company’s customers have significant variations in their purchasing patterns, as can be seen from our quarterly results over the past few years. COVID 19 had a significant impact, as customers increased their purchases in F2022 for fear of supply chain interruptions. Our sales softened somewhat as some of those customers worked off those inventories in F2023. On a positive note, our largest market (hemostasis) continues to grow at a rapid pace which we expect to continue into F2024. Customers in other markets appear to be working off their inventory cushion, which may have an impact in F2024. The Company continues to work on a number of new heparinase-containing clinical device projects with its key customers. However, as with all developmental projects, we cannot give assurances that any of these customer-driven projects will come to market and produce significant revenues. Development of DiaMaze® (diamine oxidase) continues to advance. DiaMaze® is an enzyme targeted to persons suffering from histamine intolerance and will be marketed as a nutraceutical. We continue to make good progress in the development of a commercial scale manufacturing process. The next critical development steps will be selecting a manufacturer for commercial product, and conducting toxicology studies which, if undertaken, will increase R&D expenses in fiscal 2025. ABOUT IBEX IBEX manufactures and markets proteins for biomedical use through its wholly owned subsidiary IBEX Pharmaceuticals Inc. (Montréal, QC). For more information, please visit the Company’s website at . Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Safe Harbour Statement All of the statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, are forward-looking statements. Such statements, as they are based on the current assessment or expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which IBEX does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. IBEX disclaims any intention or obligation to update these statements, except if required by applicable laws. In addition to the risk factors identified above, IBEX is, and has been in the past, heavily reliant on three products and five customers, the loss of any of which could have a material effect on its profitability. Contact: Paul Baehr President & CEO IBEX Technologies Inc. 514-344-4004 x 143

MONTRÉAL, June 07, 2023 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the third quarter and the nine months ended April 30, 2023. According to Paul Baehr, IBEX President and CEO, “Our net earnings for the quarter increased 57% versus the same period year ago. Revenues were up 2% for this reporting period, well above expectations based on the extremely strong F2022 where customers had built inventories due to COVID concerns regarding supply chain interruptions. However, when compared to the same period in fiscal 2021, revenues were up 54%.” He further stated, “We now expect F2023 revenues, while lower than the exceptional 2022 fiscal year, to be significantly higher than fiscal year 2021. The engine for this growth is the underlying increasing demand and market penetration of our major customers in the high-growth, hemostasis-rapid-testing market segment.” Note: All figures are in Canadian dollars unless otherwise stated. The Company’s audited consolidated financial statements for the year ended July 31, 2022, and the accompanying notes and the related management’s discussion and analysis can be found on the Company’s website at or under the Company’s pro SEDAR at . FINANCIAL RESULTS FOR THE THIRD QUARTER OF FISCAL 2023 Revenues for the quarter ended April 2023, totaled $2,264,196, up $54,962 from $2,209,234 for the same period the prior year, and 54% higher than the same period in fiscal 2021. Fiscal 2023 revenues were higher than expected which we attribute to higher foreign exchange rates as well as to underlying growth of the market segments in which we compete which has the effect of depleting the inventories build up in F2022 faster than forecasted. Net expenses totaled $1,372,765, a decrease of $266,867 versus $1,639,632. The decrease is mainly due to lower financial expenses of $100,466 as a result of an increase in interest income; the recording of the SR&ED tax credits of $195,617, offset mainly by an increase in R&D expenses of $52,607. Net earnings totaled $891,431, an increase of $321,829 as compared to Q3 FY2022, as explained above. The Company recorded EBITDA of $919,650 versus $686,674 in the same period a year ago, an increase of $232,976 mainly due to the increase in earnings, partially offset by the increase in interest income (interest income is excluded from the EBITDA calculation). It should be noted that “EBITDA” (Earnings Before Interest, Tax, Depreciation & Amortization) is not a performance measure defined by IFRS, but we, as well as investors and analysts, consider that this performance measure facilitates the evaluation of our ongoing operations and our ability to generate cash flows to fund our cash requirements, including our capital expenditures program. Note that our definition of this measure may differ from the ones used by other public corporations. EBITDA for the three months ended April 30, 2023 April 30, 2022 Net earnings $891,431 $569,602 Depreciation of property, plant, equipment and intangible assets $47,202 $35,531 Depreciation of right-of-use assets $65,769 $58,056 Interest – Net ($75,972 ) $23,485 Income tax expense (recovery) (8,780 ) - Earnings before interest, tax, depreciation and amortization $919,650 $686,674 FINANCIAL RESULTS FOR THE NINE MONTHS ENDED APRIL 30, 2023 Revenues for the nine months ended April 30, 2023, totaled $5,737,837, a decrease of $84,636 as compared to $5,822,473 in the same period of the prior year, but 45% higher than the same period in fiscal 2021. Fiscal 2023 revenues were higher than expected which we attribute to the impact of higher foreign exchange rates as well as to the underlying growth of the market segments in which we compete. Net year-to-date expenses totaled $4,067,866, a decrease of $114,976. The drop relates mainly to a significant decrease in financial expenses of $222,692, due to higher interest income on our cash balances, as well as to the positive impact of SR&ED tax credits for FY2022 and FY2023 ($195,617). These two factors are partially offset by an increase in R&D expenses of $290,911, relating mainly to the diamine oxidase (DiaMaze®) development program. Net earnings totaled $1,669,971, up $30,340 vs the same period year ago as a result of a decrease in net expenses of $114,976 offset by a decrease in revenues of $84,636. The Company recorded EBITDA of $1,778,130, a decrease of $167,538 vs. $1,945,668 in the same period year ago despite the slight increase in net earnings. The difference is attributed mainly to an increase in net interest of $226,242 due to higher interest income on our cash balances, which is excluded from EBITDA. Financial Summary for the nine months ended April 30, 2023 April 30, 2022 Revenues $5,737,837 $5,822,473 Earnings before interest, tax, depreciation & amortization (EBITDA) $1,778,130 $1,945,668 Depreciation of property, plant, equipment and intangible assets $117,889 $114,844 Depreciation of right-of-use assets $197,270 $163,094 Net earnings $1,669,971 $1,639,631 Earnings per share $0.06 $0.06 EBITDA for the nine months ended April 30, 2023 April 30, 2022 Net earnings $1,669,971 $1,639,631 Depreciation of property, plant, equipment and intangible assets $117,889 $114,844 Depreciation of right-of-use assets $197,270 $163,094 Interest - Net ($198,220 ) $28,099 Income tax expense ($8,780 ) - Earnings before interest, taxes, depreciation and amortization $1,778,130 $1,945,668 The Company’s substantial cash balance of $7,518,058 decreased by $122,994 despite a strong EBITDA. This was mainly due to the timing of a receivable, the purchases of production related fixed assets and the payout of the FY2022 Profit-Sharing Plan (PSP) which was recorded in Q4 F2022. Net working capital increased by $1,119,716 during the nine months ended April 30, 2023, as compared to the year ended July 31, 2022, due to strong earnings, despite significant purchases of production related fixed assets during the year. Balance Sheet Summary as at April 30, 2023 July 31, 2022 Cash and cash equivalents $ 7,518,058 $ 7,641,052 Net working capital $ 8,394,049 $ 7,274,333 Outstanding shares at report date (common shares) 24,784,244 24,823,244 LOOKING FORWARD As always, the future financial results of the Company are difficult to predict as the Company’s customers have significant variations in their purchasing patterns, as has been illustrated in the quarterly results over the past few years. The impact of COVID-19 added further variability. Our expectation for F2023 was that we would experience a significant revenue downturn as customers worked off their inventory excess, but to date we have not seen such an effect. We attribute this mainly to the underlying strength of the markets we serve. We may see some softening in the fourth quarter, but the positive trend points to IBEX generating net earnings significantly higher than F2021, although not approaching the extraordinary F2022. Looking beyond Fiscal 2023, the future looks very favorable for IBEX as the market for hemostasis testing grows at a rapid pace, driven by the accelerated adoption of the new rapid viscoelastic testing devices. The Company continues to work on a number of new heparinase-containing clinical device projects with its key customers, some of which may result in additional revenues in Fiscal 2023. However, as with all developmental projects, we cannot give assurances that any of these customer-driven projects will come to market and produce significant revenues. Development of DiaMaze® (diamine oxidase) continues to advance. DiaMaze® is an enzyme targeted to persons suffering from histamine intolerance and will be marketed as a nutraceutical. We continue to make good progress in the development of a commercial scale manufacturing process. The next critical development steps will be selecting a manufacturer for commercial product, and conducting toxicology studies which, if undertaken, will increase R&D expenses considerably in fiscal 2024. ABOUT IBEX IBEX manufactures and markets proteins for biomedical use through its wholly owned subsidiary IBEX Pharmaceuticals Inc. (Montréal, QC). IBEX Pharmaceuticals also manufactures and markets a series of arthritis assays, which are widely used in osteoarthritis research. For more information, please visit the Company’s website at . Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Safe Harbor Statement All of the statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, are forward-looking statements. Such statements, as they are based on the current assessment or expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which IBEX does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. IBEX disclaims any intention or obligation to update these statements, except if required by applicable laws. In addition to the risk factors identified above, IBEX is, and has been in the past, heavily reliant on three products and five customers, the loss of any of which could have a material effect on its profitability. Contact: Paul Baehr President & CEO IBEX Technologies Inc. 514-344-4004 x 143

关键词肌萎缩侧索硬化症；Qalsody；研究进展肌萎缩侧索硬化症（ALS），俗称“渐冻症”，是一种渐进和致命的神经退行性疾病，由来自大脑和脊髓的运动神经元缺失引起，可导致四肢、躯干、胸部、腹部肌肉逐渐无力并萎缩，从而影响运动、交流、吞咽和呼吸功能，最终致死。据统计，全球范围内每10000人中大约有6-9个ALS患者，且患病率逐年增长。目前，ALS发病机制并不十分明确。据2023年3月英国谢菲尔德大学谢菲尔德转化神经科学研究所Pamela J. Shaw团队在Nature Reviews Drug Discovery期刊上发表的文章，ALS发病与遗传、氧化应激、兴奋性毒性、神经炎症反应、线粒体功能紊乱、DNA和RNA损伤、蛋白稳态受损、轴突损伤等有关，这些因素相互作用导致患者出现运动神经元损伤。复杂的发病机制导致ALS药物研发十分困难，目前全球获批治疗ALS的药物非常有限，已获批的药物包括利鲁唑、依达拉奉、Relyvrio和Qalsody。利鲁唑是是第一个获FDA和欧盟批准用于治疗ALS的药物。作为神经保护剂，利鲁唑可改善病人生存状态，但却无法阻止ALS病情的发展，目前已获批的剂型包括片剂、口腔膜剂和混悬剂。依达拉奉是一种脑保护剂（自由基清除剂），为期6个月的临床试验证明其能够减缓ALS相关的日常功能衰退。目前，已获批的剂型有静脉注射剂（如Radicava）和口服混悬剂（如Radicava ORS）。Relyvrio是苯丁酸钠(PB)和牛磺酸二醇(TURSO)组成的复方制剂，其靶向ALS和其他神经退行性疾病中的内质网和线粒体依赖性神经元退行性变通路，减少神经元死亡和功能障碍，可显著减缓ALS疾病进展和延长生存期。2022年，Relyvrio先后在加拿大和美国被批准用于治疗成人ALS。Qalsody（tofersen）是Ionis研发的一种反义寡核苷酸（ASO)药物，它能够与编码SOD1的 mRNA结合，被核糖核酸酶RNase-H降解，从而减少突变SOD1蛋白的生成。2023年4月，Qalsody被FDA批准用于治疗超氧化物歧化酶1 (SOD1)突变所致的ALS。此外，目前全球还有多款在研ALS新疗法，详见下表。在研ALS疗法药物类型多样，涉及间充质干细胞疗法、基因疗法（ASO疗法和腺相关病毒（AAV）介导基因疗法）、Treg细胞疗法等，且有多款进入临床后期。全球部分在研ALS药物来源：公开资料01干细胞疗法干细胞疗法可以通过多种途径进行神经损伤修复，具有治疗ALS等多种中枢神经系统疾病潜力。过去十几年，ALS干细胞疗法的开发和临床转化取得了巨大的成就，据不完全统计，clinicaltrials官网登记的干细胞治疗ALS的临床研究数量超过40项。其中间充质干细胞作为能够保护运动神经元（MN）、分化为多种神经细胞类型、调节免疫细胞作用和减少中枢神经系统（CNS）炎症的细胞而脱颖而出。据悉，Corestem公司的间充质干细胞疗法NeuroNata-R已于2014在韩国获有条件批准用于治疗ALS，目前NeuroNata-R 联合利鲁唑治疗ALS的3期临床试验正在进行中。此外，Brainstorm公司的间充质干细胞疗法NurOwn®进展也较快。2020年11月，Brainstorm宣布NurOwn®在治疗ALS的3期临床试验中未能达到主要终点指标和关键次要终点，不过NurOwn®在病情较轻的患者组中产生了具有临床意义的作用。2022年11月，FDA在未对NurOwn®的BLA进行审查情况下就否决了其上市申请。02基因疗法自1993年发现第一个ALS致病基因，迄今为止，已有近30个基因被证实与ALS的发病相关，最常见的致病基因突变主要包括SOD1、TARDBP、FUS、OPTN、SQSTM1、DAO、DCTN1、VAPB、SIGMAR1、GRN、C9orf72等。近30年来，全球多款治疗ALS的基因疗法已进入临床试验阶段。在研ALS基因疗法包括反义寡核苷酸（ASO）疗法、腺相关病毒（AAV）介导的基因沉默/传递等多种创新疗法，其中首款治疗ALS的ASO药物Qalsody已于今年4月在美国获批。此外，ASO疗法中的ION363进展也较快，目前已进入3期临床。ION363是一种针对FUS RNA的反义药物，可减少FUS蛋白的产生。在FUS-ALS小鼠模型中，反义介导的突变FUS蛋白的还原可防止运动神经元丢失。通过针对FUS-ALS的根本原因，ION363具有减少或预防FUS-ALS患者疾病进展的潜力。2021年4月，ION363治疗FUS突变ALS患者的3期临床试验启动。WAVELife Sciences开发WVE-004是的一款针对C9orf72基因突变导致的ALS和额颞叶痴呆（FTD）的ASO药物，旨在选择性靶向含有与C9orf72基因相关的六核苷酸重复扩增（G4C2）的转录变体，从而保留C9orf72蛋白。C9orf72中的G4C2扩增是ALS和FTD散发性和遗传性形式的最常见遗传原因之一。目前， WVE-004正在进行一项针对42名与C9ORF72相关的ALS或FTD患者的1/2期安全性研究。AAV介导的ALS基因疗法进展相对较慢，其中Apic Bio开发APB-102由重组AAVrh10载体组成，该载体表达微核糖核酸（miRNA），旨在敲低SOD1的表达，目的是减缓或潜在逆转SOD1突变患者ALS的进展，目前已进入1/2期临床。Eikonoklastes Therapeutics的ET-101（SynCav1）是由加州大学圣地亚哥分校Brian Head博士实验室首创，用于过表达Caveolin-1的一种AAV9基因疗法，Caveolin-1可以组织和调节神经肌肉信号传导和功能所必需的突触受体。研究结果显示，增加Caveolin-1可以对神经细胞产生保护作用，使神经细胞可以补偿潜在疾病引起的神经退行性过程，并且使得细胞保持健康并提高其功能性。2022年12月，ET-101获得FDA孤儿药认定，用于治疗散发性和家族性ALS。03其他药物Treg细胞疗法也被开发用于治疗ALS，如ALS001。ALS001是一种自体的Treg细胞疗法，已被FDA授予的孤儿药资格。其1期临床结果表明，ALS001能够对神经起到保护作用，减缓ALS的进展。此外，Atibuclimab、Tegoprubart（AT-1501）等单抗也开发用于治疗ALS。其中Atibuclimab是一款靶向CD14的单克隆抗体，由小鼠可变区和人类IgG4 Fc区组成，可调节感染和损伤引发的致病性炎症反应。2021年1月，FDA授予Atibuclimab治疗ALS的孤儿药资格。Tegoprubart是一种靶向CD40L单抗，可阻断CD40L通路的激活，在ALS的临床前动物模型显示，CD40L通路可以改善肌肉功能、延缓疾病进展和提高存活率。在健康志愿者和患有ALS的成人开展的1a/1b期单次递增剂量试验显示，Tegoprubart在所有剂量下都表现出良好的耐受性，并显示出良好的安全性。而且，Tegoprubart在整个剂量范围内显示出线性剂量比例，半衰期长达26天。已公布的Tegoprubart治疗ALS的2a期临床试验结果显示：Tegoprubart表现出良好的耐受性，以及降低炎症相关生物标志物水平的作用。总结肌萎缩侧索硬化症(ALS)被WHO列为与艾滋病、癌症、白血病、类风湿等并列的五大绝症之一，然而目前该领域获批药物有限，ALS患者3年和5年死亡率分别为50%和80%。随着研究的深入，基因疗法、细胞疗法等药物治疗ALS的潜力已显现，期待未来有更好的ALS疗法获批上市，造福广大ALS患者。END👇关注药渡数据媒体矩阵